Cross River Expands Borderless Finance with Launch of International Payments Powered by Smart-Routing
FORT LEE, N.J.--(BUSINESS WIRE)--Apr 30, 2025--
Cross River Bank ('Cross River'), a technology infrastructure provider that offers embedded financial solutions, today announced the launch of its new International Payments solution, now processing transactions with Aion, a modern business finance platform designed to simplify financial management. Leveraging Cross River's proprietary banking core, API technology, and industry-leading compliance and AML/CFT integrations, this new International Payments solution offers seamless, efficient, and cost-effective cross-border transactions for businesses.
With the demand for cross-border payments increasing, and the market forecasted to reach $320tn by 2032, the need for efficient and secure international payment systems is increasingly important. Cross River's International Payments platform is rail-agnostic, dynamically selecting the most relevant payment rails based on transaction size, currency, and corridor. This ensures businesses and consumers benefit from faster processing times so consumers receive their money when and where they need it.
'Our goal is to simplify cross-border payments by removing technical barriers that limit global scalability,' said Luca Cosentino, Head of Product at Cross River. 'Our International Payments capability uses a flexible, rail-agnostic approach to enable fast, cost-effective, and secure transfers—whether through SWIFT or local bank rails. This milestone not only marks a significant advancement in our infrastructure but also sets the stage for future real-time global payment solutions that help our partners deliver seamless international experiences.'
Cross River's solution offers businesses a range of payment pathways—from SWIFT for secure, standardized cross-border transactions to local bank rails optimized for domestic B2B and B2C transfers. The capability initially enables cross-border payments for fintechs and SMBs, B2B and B2C transfers, funding operating accounts and subsidiary payments back to parent companies.
An early adopter of Cross River's International Payments is Aion, a modern business finance platform designed to simplify financial management. Cross River and Aion have previously partnered to enable instant payments domestically via RTP ® and FedNow ®, as well as traditional methods such as ACH, same-day ACH and Wires. Cross River also provides business banking accounts through Aion, including a High-Yield Business Account *. Aion's commercial-grade all-in-one banking solution helps streamline business payments, now internationally with Cross River's solution.
'SMBs are the backbone of the global economy, yet they've long faced high costs and delays when paying international suppliers or remote teams,' said Satish Palvai, Founder and CEO at Aion. With Cross River's International Payments, we're leveling the playing field by giving growing businesses access to the same speed and efficiency once reserved only for large enterprises.'
With strict adherence to regulatory standards, Cross River's International Payments platform integrates advanced anti-money laundering (AML) tools and compliance solutions. Fully routable subledgers and detailed customer records allow businesses to monitor transactions on a sub-entity level, ensuring security and reliability.
This launch marks just the beginning of the Bank's commitment to powering borderless finance. Cross River will continue to invest in expanding supported use cases, countries, and currencies—enhancing the infrastructure to meet the evolving needs of fintech partners and enabling more businesses and consumers to move money globally with speed, security, and confidence.
About Cross River
Cross River provides technology infrastructure powering the future of financial services. Leveraging its proprietary real-time banking core, Cross River delivers innovative and scalable embedded payments, cards, and lending solutions to millions of consumers and businesses. Cross River is backed by leading investors and serves the world's most essential fintech and technology companies. Leading the industry, Cross River is reshaping global finance and financial inclusion. Member FDIC. Find out more at www.crossriver.com.
About Aion
Aion is a modern business finance platform, designed to simplify financial management. The company's mission is to enable business owners and finance professionals to focus on building and growing their businesses, while AI-powered software handles the rest. The Aion's platform is founded on the principles of customer-centric exceptional design, simplicity, and transparency. Find out more at https://aionfi.com.
For press inquiries, please contact Christopher Basso at [email protected].
*Aion is a financial technology company, not a bank. Banking Services provided by Cross River Bank, Member FDIC. Aion accounts are FDIC insured up to $250,000 per depositor through Cross River Bank, Member FDIC. Banking Services for payments made via ACH or wire from the Aion Business Checking Account are provided by Cross River Bank, Member FDIC. The Aion Business Debit Visa® is issued by Cross River Bank, Member FDIC pursuant to a license from Visa, Inc., and may be used everywhere Visa is accepted.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250430972311/en/
CONTACT: Media Contact:
Mackenzie DeLuca
[email protected]
201-808-7000 x 778
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: SOFTWARE PAYMENTS FINANCE ARTIFICIAL INTELLIGENCE BANKING PROFESSIONAL SERVICES TECHNOLOGY FINTECH
SOURCE: Cross River Bank
Copyright Business Wire 2025.
PUB: 04/30/2025 08:30 AM/DISC: 04/30/2025 08:29 AM
http://www.businesswire.com/news/home/20250430972311/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ('CERo'), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred Stock to certain institutional investors (the 'Investors') pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22, 2025 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million, including $5 million previously issued in April 2025 and up to $3 million issuable at the option of the Investors. The shares of Series D Preferred Stock are convertible into shares of the Company's common stock. 'We welcome this vote of confidence and the continued support of our investors as we continue to show progress along our clinical timeline. The completion of our first-in-human dosing represents a significant clinical development milestone in AML for CER-1236, a novel autologous CAR-T therapeutic candidate targeting TIM 4L, and we will continue to communicate results as the data matures,' said Chris Ehrlich, Chief Executive Officer. The gross proceeds to CERo from today's closing are expected to be approximately $750,000, with up to $2.25 million of cash that may be funded at one or more additional closings, at the election of the Investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. In April 2025, CERo initiated clinical trials for its lead product candidate, CER-1236,for hematological malignancies. Forward-Looking Statements This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact:Chris EhrlichChief Executive Officerchris@ Investors:CORE IRinvestors@ in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the 'Company') (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the 'Compensation Committee') granted inducement awards consisting of nonstatutory stock options to purchase 79,200 shares of common stock to five (5) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price equal to $6.30 per share, the Company's closing sales price on June 2, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company's 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration ('FDA') for the treatment of relapsed/refractory ('R/R') NPM1-mutant acute myeloid leukemia ('AML'). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA's acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn. Contacts Investors:Patti BankManaging Director(415) Media:media@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 hours ago
- Yahoo
XRP vs. Bitcoin: Which Wins During Trump's Tariff War?
Tariff headlines may hammer Bitcoin in the short term, but they won't in the long term. XRP could gain in relevance as new trade routes demand faster cross-border liquidity. We haven't heard the last word on tariff policy just yet. 10 stocks we like better than Bitcoin › Farmers once watched the sky for storm fronts, and today, investors track the president's unpredictable tariff tweets. In early April, President Donald Trump slapped a blanket 10% levy on all imports, with even steeper surcharges for a handful of unlucky trading partners. Gold promptly ripped to record prices as investors flocked to safe assets. The crypto market's response has been a bit harder to read. Bitcoin (CRYPTO: BTC) shed 2.5% the morning Trump floated a 50% E.U. tariff. Meanwhile, XRP (CRYPTO: XRP) currently hugs $2.20 after a quiet month. Two assets, two very different narratives, and one messy set of tariff policies that seem to keep changing. Which asset looks sturdier right now? Let's dive in and figure it out. Gold's 21% climb this year so far underscores a simple idea. When policy risk jumps, capital chases scarcity. Bitcoin sells that same scarcity story as part of the core of its investment thesis. Only 512 new coins are mined daily, and the crypto's price is up by 11% this year so far. Still, tariffs sap global liquidity via higher input costs and slower trade. That tilts short-term flows toward cash, not volatile assets. Bitcoin's move since Trump's April decree shows its perceived safety status remains largely unproven and conditional on risk appetite. Assuming the White House follows through with more sector-specific tariffs as the president keeps claiming, Bitcoin could experience doldrums until the ongoing uncertainty passes. Over the longer haul, though, its margin of safety is driven by supply, not headlines. If broad tariffs weaken the dollar, a non-fiat-currency store of value with deep liquidity may absorb the same inflation hedge inflows that gold currently enjoys. That edge would be structural and long-lasting, if it happens. Bitcoin may win the narrative war over the long haul, but XRP is quietly winning contracts that increase its value today. Ripple, which issues XRP, announced on May 19 that it had expanded the chain's network to include Zand Bank and a fintech called Mamo, both of which are based in the U.A.E. Tariffs reroute supply chains, creating new bilateral corridors across which money needs to flow smoothly. It's easier for that to happen with solutions that natively comply with local regulations. On that note, XRP's relatively new and built-in account-freeze, blacklist, and trustline features let banks satisfy know-your-customer (KYC) and anti-money laundering (AML) rules without requiring the patchwork of fixes that other blockchains might. If tariff policy turbulence endures, XRP's cross-border payment volume should grow even if the overall volume of trade shrinks, because companies can fragment production to dodge duties, and there's always an incentive to cut costs. XRP's niche, cheaply settling money transfers across borders, could see persistent throughput gains. Yet investors must recall that these flows translate into modest net buying of XRP for liquidity, not necessarily long-term locking as with Bitcoin purchased for holding. Which asset fares better depends on your investing timetable and risk tolerance. Bitcoin's upside rests on scarcity, which isn't going anywhere regardless of tariffs (or the lack thereof). It's the more conservative choice. Therefore, long-term oriented investors who want a digital alternative to gold may prefer Bitcoin's proven scarcity and growing status as an investment that institutions want to hold. A slowdown in the global economy can hit Bitcoin too, but it's hard to envision pretty much anything short of a total collapse bringing it to a halt. XRP offers a different risk curve. XRP is the riskier and more volatile investment, but it likely has a better chance of growing faster over the next year or perhaps even longer due to its actual utility. Its utility as a payment processor and money transfer platform means that demand for the coin rises when trade friction rises, but it isn't scarce at all. More supply is unlocked from escrow each month. Meanwhile, any setback in Ripple's regulatory diplomacy could freeze adoption overnight. No outcome is guaranteed here. It might be a good move to buy both coins, provided you're willing to hold them. Before you buy stock in Bitcoin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Bitcoin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Alex Carchidi has positions in Bitcoin. The Motley Fool has positions in and recommends Bitcoin and XRP. The Motley Fool has a disclosure policy. XRP vs. Bitcoin: Which Wins During Trump's Tariff War? was originally published by The Motley Fool Sign in to access your portfolio
